Literature DB >> 20619660

Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables.

Tülay Terzi1, Murat Terzi, Berna Tander, Ferhan Cantürk, Musa Onar.   

Abstract

Bone mineral density (BMD) is affected in young adults with multiple sclerosis (MS), which leads to disabling disease. We aimed to show changes that were independent of immobilization by measuring BMD and laboratory markers of bone metabolism in mobile MS patients. We compared a total of 52 premenopausal female patients with relapsing-remitting multiple sclerosis (RRMS) to 41 women of similar age who had no risk factors for osteoporosis. The lumbar and femur BMD were measured using the dual energy X-ray absorptiometry (DXA) method. The urine concentration of serum 25-hydroxycholecalciferol (25-OH vit D(3)), and pyridinoline and deoxypyridinoline were also measured. The concentration of serum osteocalcin was measured to determine the speed of bone metabolism. The mean age of patients (+/- standard deviation [SD]) was 36.1+/-7.4. The average Expanded Disability Status Scale (EDSS) score was 2.2+/-1.8. The concentration of 25-OH vit D(3) and osteocalcin was lower, whereas the concentration of parathyroid hormone (PTH), alkaline phosphatase (ALP), pyridinoline and deoxypyridinoline was higher in the patient group. In the patient group, lumbar 2-4 BMD, T score and Z score and femur neck and trochantor BMD, T score and Z score were significantly lower than in the control group. There was a significant negative relationship between: the disease period and L 2-4 BMD, T score and Z scores; and the femoral neck BMD, T score and Z scores. There was a significant relationship between the total Functional Independence Measure score and the femoral neck, femoral trochanter BMD, T score, and Z score. There was a significant negative relationship between the average EDSS, L 2-4 and all the DXA measurements obtained from the femur. There was a significant relationship between the 25-OH vit D(3) concentration and L 2-4 T score and Z score from the DXA measurements obtained from the femur. There were no significant relationships between osteocalcin, pyridinoline, deoxypyridinoline levels and the BMD measurements. Therefore, the duration of the disease and decrease in functional capacity are the main factors that affect BMD in MS. Apart from the decrease in functional capacity, 25-OH vit D(3) deficiency and secondary PTH increase contribute to the BDM changes observed in MS. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20619660     DOI: 10.1016/j.jocn.2010.01.044

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  12 in total

Review 1.  Cardiovascular Autonomic Dysfunction: Link Between Multiple Sclerosis Osteoporosis and Neurodegeneration.

Authors:  Zohara Sternberg
Journal:  Neuromolecular Med       Date:  2018-02-10       Impact factor: 3.843

2.  Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study.

Authors:  Stine Marit Moen; Elisabeth Gulowsen Celius; Leiv Sandvik; Magritt Brustad; Lars Nordsletten; Erik Fink Eriksen; Trygve Holmøy
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

Review 3.  Bone health in multiple sclerosis.

Authors:  J C Gibson; G D Summers
Journal:  Osteoporos Int       Date:  2011-05-21       Impact factor: 4.507

4.  Bone mass in Saudi women aged 20-40 years: the association with obesity and vitamin D deficiency.

Authors:  Mai Albaik; Jalaluddin A Khan; Ikhlas Sindi; Kristina E Akesson; Fiona E A McGuigan
Journal:  Arch Osteoporos       Date:  2022-09-15       Impact factor: 2.879

Review 5.  Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.

Authors:  S Binks; R Dobson
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

6.  Correlation of circulating omentin-1 with bone mineral density in multiple sclerosis: the crosstalk between bone and adipose tissue.

Authors:  Majid Assadi; Hooman Salimipour; Samad Akbarzadeh; Reza Nemati; Syed Mojtaba Jafari; Afshar Bargahi; Zahra Samani; Mohammad Seyedabadi; Zahra Sanjdideh; Iraj Nabipour
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

7.  Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial.

Authors:  Linn H Steffensen; Lone Jørgensen; Bjørn Straume; Svein Ivar Mellgren; Margitta T Kampman
Journal:  J Neurol       Date:  2011-03-13       Impact factor: 4.849

8.  Is serum vitamin D levels associated with disability in patients with newly diagnosed multiple sclerosis?

Authors:  Hamidreza Hatamian; Elham Bidabadi; Seyed Mohammad Seyed Saadat; Niloufar Seyed Saadat; Ehsan Kazemnezhad; Hamed Ramezani; Babak Bakhshayesh
Journal:  Iran J Neurol       Date:  2013

9.  Lack of Association between Pulse Steroid Therapy and Bone Mineral Density in Patients with Multiple Sclerosis.

Authors:  Serap Zengin Karahan; Cavit Boz; Sevgi Kilic; Nuray Can Usta; Mehmet Ozmenoglu; Vildan Altunayoglu Cakmak; Sibel Gazioglu
Journal:  Mult Scler Int       Date:  2016-02-04

10.  Assessment of Biochemical and Densitometric Markers of Calcium-Phosphate Metabolism in the Groups of Patients with Multiple Sclerosis Selected due to the Serum Level of Vitamin D3.

Authors:  Natalia Niedziela; Krystyna Pierzchała; Jolanta Zalejska-Fiolka; Jacek T Niedziela; Ewa Romuk; Magdalena Torbus-Paluszczak; Monika Adamczyk-Sowa
Journal:  Biomed Res Int       Date:  2018-08-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.